Glofitamab in combination with gemcitabine hydrochloride and oxaliplatin for the treatment of patients with relapsed or refractory diffuse large Bcell lymphoma

29 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Dupilumab for the treatment of adults with severe chronic rhinosinusitis with nasal polyps (review of TA648)

23 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Thousands could benefit from first immunotherapy for severe birch tree pollen allergy

21 July 2025 - We have recommended the first under the tongue tablet immunotherapy shown to build long-term tolerance to allergens, ...

Read more →

Amivantamab in combination with lazertinib for the first-line treatment of patients with advanced EGFR mutation positive non-small cell lung cancer

4 July 2025 - The Department of Health and Social Care has NICE to produce guidance on the use of ...

Read more →

Thousands more breast cancer patients to benefit from new NHS treatment

17 July 2025 - NICE approves ribociclib combination therapy to help prevent cancer returning in early stage disease. ...

Read more →

New cystic fibrosis drug fast tracked for NHS use

15 July 2025 - Some people with cystic fibrosis are set to benefit from a new once daily triple therapy treatment, ...

Read more →

Vertex announces broad reimbursement agreement with NHS England for Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) an innovative once daily CFTR modulator for the treatment of cystic fibrosis

14 July 2025 - All eligible people with cystic fibrosis in England can now benefit from this medicine - ...

Read more →

Delgocitinib for the treatment of patients with moderate to severe chronic hand eczema

8 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma

10 July 2025 - NICE has published final evidence-based recommendations on the use of zanubrutinib for the treatment of adults ...

Read more →

Garadacimab for the prevention of recurrent attacks of hereditary angioedema in patients 12 years of age and older

2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Teprotumumab for the treatment of patients with thyroid eye disease

2 July 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Adagrasib for adults with previously treated, advanced, KRAS G12C mutation positive non-small-cell lung cancer

2 July 2025 - NICE is unable to make a recommendation on the use of adagrasib (Krazati) for the second-line treatment ...

Read more →

Pegzilarginase for the treatment of patients 2 years of age and older with arginase-1 deficiency

26 June 2025 - NICE has published additional draft guidance consultation on the use of pegzilarginase in the NHS in ...

Read more →

Final draft guidance finds benefits of two treatments for patients with Alzheimer’s disease remain too small to justify the additional cost to the NHS

19 June 2025 - The benefits from donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai) - remain too small to justify ...

Read more →

Tislelizumab for the treatment of adults with advanced non-small-cell lung cancer after platinum-based chemotherapy

19 June 2025 - NICE is unable to make a recommendation on the use of tislelizumab (Tevimbra) for the treatment of ...

Read more →